NCT01327846: Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
- State
- Completed
- Phase
- Phase 3
- People
- 10,066 taking part
- Started
- 11 Apr 2011
- Primary completion
- 28 Mar 2017
- Arms
- Canakinumab Dose 50 mg, Canakinumab Dose 150 mg, Canakinumab Dose 300 mg
- Results
- Posted on the registry
- 4 Apr 2011: Trial registered
- 11 Apr 2011: Trial started
- 14 Apr 2019: Trial completed
- 22 Jan 2020: Trial results posted